Table 3 Association of baseline characteristics and COVID-19 treatment with presence of long COVID symptoms. Variables are summarized by sample sizes and percentages, stratified by the presence and absence of COVID. Chi square test for independence were used to calculate the p-values for each of the variables
Fully Vaccinated cohort | |||||
|---|---|---|---|---|---|
Variables | Presence of long COVID (n = 164) | Absence of long COVID (n = 250) | OR (95%CI) | p value | |
Age > 65 | 57 (74%) | 20 (26%) | 6.13(3.5-10.71) | < 0.001* | |
Age < 65 | 107 (32%) | 230 (68%) | |||
Male | 84 (42%) | 118 (58%) | 1.17 (0.79–1.74) | 0.242 | |
Female | 80 (37%) | 132 (63%) | |||
Type II DM | 59 (64%) | 33 (36%) | 3.69 (2.27-6) | < 0.001* | |
Hypertension | 78 (72%) | 30 (28%) | 6.65 (4.08–10.85) | < 0.001* | |
DLP | 28 (70%) | 12 (30%) | 4.08(2.01–8.29) | < 0.001* | |
Hypothyroidism | 17 (52%) | 16 (48%) | 1.69 (0.83–3.45) | 0.193 | |
CLD | 21 (62%) | 13 (38%) | 2.68 (1.3–5.51) | 0.01* | |
CKD | 8 (40%) | 12 (60%) | 1.02 (0.41–2.54) | 0.613 | |
Asthma | 14 (70%) | 6 (30%) | 3.8 (1.43–10.09) | 0.008* | |
COPD | 7 (44%) | 9 (56%) | 1.19 (0.44–3.27) | 0.797 | |
CAD | 8 (80%) | 2 (20%) | 6.36 (1.33–30.33) | 0.017* | |
Cancer | 7 (70%) | 3 (30%) | 3.72 (095-14.58) | 0.04* | |